



# CORECYTE™

Cord Tissue Allograft Suspension

CORECYTE™ is a minimally manipulated tissue derived from umbilical cord tissue for homologous use. CORECYTE™ is intended to supplement and replace damaged or inadequate connective tissue and cells.

CORECYTE™ contains a variety of growth factors, cytokines, hyaluronic acid and mesenchymal stem cells. The CORECYTE™ MSCs have a much higher rate of proliferation when compared to MSCs derived from either adipose or bone marrow.<sup>1</sup>

## Treatment Areas

- Large joints (Knee, Hip, Shoulder & Ankle)
- Chronic partial rotator cuff tears
- Persistent partial tendon tears (Tennis Elbow)
- Plantar fasciitis / Bone Spurs
- Quadriceps and patellar tendon tears
- Muscular tears
- Meniscus and cartilage tears
- Intervertebral disc and spinal facet joints
- Radicular and Sacroiliac nerves / Pinched nerves



## ADVANTAGES OF CORECYTE™

1. The use of the CORECYTE™ product is less invasive when compared bone marrow aspiration, or adipose tissue extraction. This results in less pain for the patient and a much shorter procedure time.
2. CORECYTE™ does not use any material obtained directly from the embryo or fetus.
3. Because umbilical cord MSC's lack MHC-II and are therefore hypo-immunogenic, they are inherently unlikely to result in an allergic reaction for the recipient.<sup>2</sup>
4. Umbilical MSC's have a strong anti-inflammatory effect, reducing the expression of inflammatory cytokines. This anti-inflammatory effect is maintained as they multiply.<sup>2</sup>

CORECYTE™ is processed from donated human tissue from full term, c-section deliveries in accordance with the FDA and the American Association of Tissue Banks (AATB) standards. CORECYTE™ is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.

1. Sabapathy V, Sundaram B, VM S, Mankuzhy P, Kumar S (2014) *Human Wharton's Jelly Mesenchymal Stem Cells Plasticity Augments Scar-Free Skin Wound Healing with Hair Growth*. **PLoS ONE** 9(4): e93726. doi:10.1371/journal.pone.0093726

2. F Gao et.al. *Mesenchymal stem cells and immunomodulation: current status and future prospects* **Cell Death and Disease** (2016) 7, e2062; doi:10.1038/cddis.2015.327.



**PREDICTIVE**  
B I O T E C H

2749 East Parleys Way, Suite 101  
Salt Lake City, UTAH 84109

Office: 1-888-407-9761

Fax: 1-801-487-2477

Email: customerservice@predrx.com